Is NYMOX PHARMACEUTICAL CORP (NYMXF) a buy?

NYMXF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Pulling SEC filings + quote and writing the call…

NYMXF

NYMOX PHARMACEUTICAL CORP

Sell

$0.12

▲ +9.09%

$0.12▲ +53.65%

over 1Y

L $0.04EODHDH $0.15

Today+9.1%

1W+9.1%

1M-7.7%

3M+60.0%

YTD+157.5%

1Y+53.6%

Sell

Conviction

Horizon

Medium (3–12mo)

Mixed signals in the latest filings.

NYMOX PHARMACEUTICAL CORP shows limited reported revenue.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$11.3M

EV / EBITDA—

EV / Sales—

EV / FCF—

P / FCF—

PEG (trailing)—

Earnings yield—

FCF yield—

Quality & risk

ROIC (est.)—

Free cash flow—

Total debt—

Net cash—

Capital returns

Buyback yield—

Dividend yield (est.)—

Shareholder yield—

Shares Δ YoY+1.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Insider activity

Form 4 · SEC

2022-05-02-05:00	Robinson James George Director	Buy	1.15M @ $1.65	$1.90M
2021-04-22	Robinson James George Director	Buy	7.00K @ $2.07	$14.5K
2021-04-22	Robinson James George Director	Buy	1.90K @ $2.13	$4.05K
2021-04-22	Robinson James George Director	Buy	3.10K @ $2.11	$6.53K
2021-04-22	Robinson James George Director	Buy	5.00K @ $2.05	$10.3K
2021-04-22	Robinson James George Director	Buy	4.95K @ $2.09	$10.3K
2021-04-22	Robinson James George Director	Buy	51.00 @ $2.08	$106.08
2021-04-22	Robinson James George Director	Buy	800.00 @ $2.10	$1.68K
2021-04-22	Robinson James George Director	Buy	2.90K @ $2.09	$6.06K
2021-04-22	Robinson James George Director	Buy	1.10K @ $2.09	$2.30K
2021-04-22	Robinson James George Director	Buy	200.00 @ $2.09	$417.00
2021-04-21	Robinson James George Director	Buy	2.00K @ $2.09	$4.18K

Congressional trades

all activity →

Disclosed under the STOCK Act

2021-02-12Greg Francis MurphySell$50.0K–$100KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →

$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtBullish

globenewswire.com· 2023-11-21

Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 MillionBearish

globenewswire.com· 2023-11-09

NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized

globenewswire.com· 2023-11-03

NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023Bullish

globenewswire.com· 2023-11-03

IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered SolicitationsBullish

globenewswire.com· 2023-11-02

IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder MeetingBullish

globenewswire.com· 2023-10-31

Recent filings

all on EDGAR ↗

Frequently asked

Is NYMOX PHARMACEUTICAL CORP (NYMXF) a buy?: NYMXF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Sources: SEC EDGAR (CIK 0001018735, latest 6-K filed 2026-06-03) · EODHD · as of 6/28/2026, 4:59:49 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.